7 results on '"Deli AM"'
Search Results
2. Helical tomotherapy for scalp recurrence of primary eccrine mucinous adenocarcinoma
- Author
-
Lara Rigoni, Micaela Motta, A.M. Deli, Elena De Martin, Filippo Alongi, Riccardo Calandrino, Nadia Di Muzio, Claudio Landoni, E. Maggiulli, Claudio Fiorino, Sara Broggi, Motta, M, Alongi, F, De Martin, E, Fiorino, C, Maggiulli, E, Rigoni, L, Landoni, C, Broggi, S, Deli, Am, Calandrino, R, Di Muzio, N, and Deli, A
- Subjects
Cancer Research ,medicine.medical_treatment ,Planning target volume ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Mucinous ,Tomography ,Dose Fractionation ,MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Radiation ,medicine.diagnostic_test ,Head and Neck Neoplasm ,General Medicine ,Adenocarcinoma, Mucinous ,X-Ray Computed ,medicine.anatomical_structure ,Oncology ,Local ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Female ,Radiology ,Human ,Simultaneous integrated boost ,medicine.medical_specialty ,Tomotherapy ,03 medical and health sciences ,medicine ,Humans ,Adenocarcinoma, Mucinou ,Aged ,Dose Fractionation, Radiation ,Neoplasm Recurrence, Local ,Positron-Emission Tomography ,Salvage Therapy ,Scalp ,Sweat Gland Neoplasms ,Tomography, X-Ray Computed ,Tomography, Spiral Computed ,Dose delivery ,business.industry ,Magnetic resonance imaging ,medicine.disease ,Surgery ,Neoplasm Recurrence ,Spiral Computed ,business - Abstract
Primary cutaneous mucinous carcinomas originating from sweat glands are rare tumors with patterns of spread that are difficult to predict. We present a case of a five times recurring eccrine mucinous adenocarcinoma of the scalp, previously treated with surgery and adjuvant radiation therapy. After magnetic resonance imaging (MRI) and 18F-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (18FDG-PET/CT), which documented local recurrence, the patient was considered eligible for salvage irradiation of the scalp. We decided to use helical tomotherapy, which combines conformity of dose delivery with the possibility of daily control of the setup accuracy. Forty gray (2Gy/fraction) to the planning target volume and 50 Gy (2.5Gy/fraction) to the biological target volume defined on the basis of 18FDGPET/CT was prescribed with a simultaneous integrated boost technique. After 12 fractions the patient was submitted to intermediate evaluation by 18FDG-PET/CT, which showed a partial response to the treatment. After 2, 4, 8, and 12 months, 18FDG-PET/CT showed a complete metabolic local response. This experience suggests a possible role of 18FDG-PET/CT-guided helical tomotherapy as an alternative to repeated and frequently demolitive surgery approaches.
3. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients.
- Author
-
Fodor A, Brombin C, Mangili P, Tummineri R, Pasetti M, Zerbetto F, Longobardi B, Galvan AS, Deantoni CL, Dell'Oca I, Castriconi R, Esposito PG, Deli AM, Rancoita PMV, Fiorino C, Vecchio AD, Di Serio MS, and Di Muzio NG
- Subjects
- Cohort Studies, Female, Humans, Mastectomy, Segmental, Middle Aged, Radiation Dose Hypofractionation, Radiotherapy, Adjuvant adverse effects, Breast Neoplasms radiotherapy, Breast Neoplasms surgery
- Abstract
Aim: To report toxicity of hypofractionated whole-breast radiotherapy in a large cohort of early-stage breast cancer (BCaients., Materials and Methods: From 02/2009-05/2017, 1325 consecutive BCa patients were treated with 40.05 Gy/15 fractions, without boost. Median age was 62 (IQR:51.1-70.5) years. Chemotherapy was prescribed for 28% of patients, hormonal therapy for 80.3%, monoclonal antibodies for 8.2%., Results: Median follow-up was 72.4 (IQR: 44.6-104.1) months. Acute RTOG toxicity was: 69.8% Grade (G) 1, 14.3% G2 and 1.7% G3. Late SOMA-LENT toxicities were: edema-hyperpigmentation (E-H): G1 28.67%, G2 4.41%, G3 0.15%; fibrosis-atrophy-telangiectasia-pain (F-A-T-P): G1 14.6%, G2 3.2%, G3 0.8%, G4 0.1%. Median time to first occurrence was 6 and 18 months, respectively. Aesthetic result after surgery was excellent in 28.7%, good in 41.5%, acceptable in 20.3% and poor in 9.5% of patients. Change in breast appearance after radiotherapy was mild in 6.9%, moderate in 2.3% and marked in 1.3% of patients. Concomitant chemotherapy, obesity, smoking, use of bolus and planning target volume (PTV) were associated with higher acute toxicity. Patients ≥55 years old were less likely to experience acute toxicity. PTV and acute G2 toxicity were associated with ≥G2 E-H. PTV, concomitant chemotherapy, hypertension and ≥G2 acute toxicity were associated with increased risk of F-A-T-P., Conclusion: Hypofractionated whole-breast radiotherapy without boost demonstrated mild acute and late toxicity in a large cohort of consecutive patients. Moderate and marked changes in breast appearance were registered for 3.6% of patients and occurred between 18 to 42 months., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
4. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
- Author
-
Fodor A, Brombin C, Mangili P, Borroni F, Pasetti M, Tummineri R, Zerbetto F, Longobardi B, Perna L, Dell'Oca I, Deantoni CL, Deli AM, Chiara A, Broggi S, Castriconi R, Esposito PG, Slim N, Passoni P, Baroni S, Villa SL, Rancoita PMV, Fiorino C, Del Vecchio A, Bianchini G, Gentilini OD, Di Serio MS, and Di Muzio NG
- Subjects
- Disease-Free Survival, Female, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Radiation Dose Hypofractionation, Receptor, ErbB-2, Breast Neoplasms radiotherapy, Breast Neoplasms surgery
- Abstract
Aim: We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost., Methods and Materials: From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa who underwent breast conservation surgery were treated with WBHF-IMRT in our institute, to a total dose of 40 Gy/15 fractions, without boost. Median age: 62 (interquartile range-IQR-:51.14-70.53) years., Histology: 8% in situ carcinoma (ISC), 92% invasive tumors. Molecular subtypes (invasive tumors): 49.9% Luminal A, 33.1% Luminal B Her2 negative (-), 6.2% Luminal B Her2 positive (+), 3.6% Hormone Receptor (HR)- Her2+, 7.1% Triple negative (TNBC), and 0.2% HR+. Chemotherapy (CT) was prescribed in 28% of patients, hormonal therapy in 80.3%, monoclonal antibodies (MAb) in 86.8% of Luminal B Her2+ and 97.7% of HR- Her2+ patients., Results: Median follow up was 72.43 (IQR: 44.63-104.13) months. The 5-year Kaplan-Meier estimates of local relapse-free survival (LRFS) was 97.8%, regional-(RRFS) 98.6%, loco-regional- (LRRFS) 96.9%, distant- (DRFS) 96.6%, disease-free survival (DFS) 94.8% and overall survival (OS) 95.5%. Considering molecular subtypes, 5-year LRFS was: 99.8% for Luminal A, 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 87.9% for HR- Her2+, 95.1% for TNBC and 99.1% for in situ carcinoma., Conclusion: While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2+ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription., Competing Interests: Declaration of competing interest Dr. Andrei Fodor reports speaker honoraria from Accuray (AERO Academy) and Janssen (Janssen Academy); personal fees for Advisory Board from Sandoz Italia, and reimbursement for travel and accommodations for congresses from Ipsen, AB Medica, Astellas, unrelated to this work. Prof. Dr. Nadia Gisella Di Muzio reports speaker honoraria from Accuray (AERO Academy) and travel and accommodation for a congress from Ipsen, unrelated to this work. Dr. Giampaolo Bianchini reports Consultancy/Advisory role for Roche, Pfizer, AstraZeneca, Lilly, Novartis, Amgen, MSD, Chugai, Sanofi, Daiichi Sankyo, EISAI, Exact Sciences, Neopharm, unrelated to this work. All the other authors have nothing to disclose. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists.
- Author
-
Furlan C, Arcangeli S, Avanzo M, Mirri MA, Munoz F, Giudici S, Perrone A, Amelio D, Tomio L, Draghini L, Deli AM, Pavanato G, Giuliano FM, Pontoriero A, Ciammella P, Navarria P, Iannalfi A, Buglione M, Guida C, Cammelli S, Iorio V, Cardinali M, Genovesi D, Barsacchi L, Balducci M, Bagnoli R, Berti F, Montesi G, Pasqualetti F, Bonome P, Santoni R, Doino D, Schirru P, Pinzi V, Borzillo V, Ferrarese F, Ferro M, Cicco L, Krengli M, Scoccianti S, and Donato V
- Subjects
- Adolescent, Combined Modality Therapy standards, Combined Modality Therapy statistics & numerical data, Female, Humans, Italy, Male, Salvage Therapy standards, Salvage Therapy statistics & numerical data, Surveys and Questionnaires, Glioma radiotherapy, Neoplasm Recurrence, Local radiotherapy, Radiation Oncologists statistics & numerical data, Re-Irradiation standards, Re-Irradiation statistics & numerical data
- Abstract
Purpose: To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach., Methods: In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach., Results: A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter <5 cm and an interval from primary radiation ≥6 months, were the prevalent predictive factors considered for reRT. Sixty percent of reirradiated patients had already received a salvage therapy, either chemotherapy (40%) or reoperation (20%). The most common approach for reRT was fractionated stereotactic radiotherapy to a mean (photon) dose of 41.6 Gy., Conclusions: Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting.
- Published
- 2018
- Full Text
- View/download PDF
6. Helical tomotherapy for scalp recurrence of primary eccrine mucinous adenocarcinoma.
- Author
-
Motta M, Alongi F, De Martin E, Fiorino C, Maggiulli E, Rigoni L, Landoni C, Broggi S, Deli AM, Calandrino R, and Di Muzio N
- Subjects
- Adenocarcinoma, Mucinous diagnosis, Aged, Dose Fractionation, Radiation, Female, Head and Neck Neoplasms diagnosis, Humans, Neoplasm Recurrence, Local diagnosis, Positron-Emission Tomography, Salvage Therapy methods, Scalp, Sweat Gland Neoplasms diagnosis, Tomography, X-Ray Computed, Adenocarcinoma, Mucinous radiotherapy, Head and Neck Neoplasms radiotherapy, Neoplasm Recurrence, Local radiotherapy, Sweat Gland Neoplasms radiotherapy, Tomography, Spiral Computed methods
- Abstract
Primary cutaneous mucinous carcinomas originating from sweat glands are rare tumors with patterns of spread that are difficult to predict. We present a case of a five times recurring eccrine mucinous adenocarcinoma of the scalp, previously treated with surgery and adjuvant radiation therapy. After magnetic resonance imaging (MRI) and 18F-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (18FDG-PET/CT), which documented local recurrence, the patient was considered eligible for salvage irradiation of the scalp. We decided to use helical tomotherapy, which combines conformity of dose delivery with the possibility of daily control of the setup accuracy. Forty gray (2Gy/fraction) to the planning target volume and 50 Gy (2.5Gy/fraction) to the biological target volume defined on the basis of 18FDG-PET/CT was prescribed with a simultaneous integrated boost technique. After 12 fractions the patient was submitted to intermediate evaluation by 18FDG-PET/CT, which showed a partial response to the treatment. After 2, 4, 8, and 12 months, 18FDG-PET/CT showed a complete metabolic local response. This experience suggests a possible role of 18FDG-PET/CT-guided helical tomotherapy as an alternative to repeated and frequently demolitive surgery approaches.
- Published
- 2009
- Full Text
- View/download PDF
7. Enhancing effect of zinc on astroglial and cerebral endothelial histamine uptake.
- Author
-
Huszti Z, Horváth-Sziklai A, Noszál B, Madarász E, and Deli AM
- Subjects
- Animals, Astrocytes metabolism, Biological Transport drug effects, Cells, Cultured, Endothelium, Vascular metabolism, Histamine physiology, Rats, Rats, Long-Evans, Rats, Wistar, Astrocytes drug effects, Endothelium, Vascular drug effects, Histamine metabolism, Zinc pharmacology
- Abstract
We have studied the effect of zinc ion on the uptake of histamine (HA) into cultured astroglial and cerebral endothelial cells and established that Zn(2+) enhances the uptake of the amine dose-dependently and in remarkable extents by increasing the V(max) to about 3-fold (from 3.25 +/- 0.42 to 8.50 +/- 0.97 pmol/mg protein/min in astroglial cells) without altering the K(M) (0.20 +/- 0.03 microM) significantly. The stimulatory effect of zinc ion showed strong sensitivity for VUF 8407, an inhibitory compound of astroglial and cerebral endothelial uptake of HA. In the presence of 20 microM VUF 8407 the zinc-enhanced uptake was reduced by about 50% in both cell types. Binding measurements revealed increased capacities of the zinc-exposed HA binding (B(max)= 0.41 +/- 0.05 increased to 1.21 +/- 0.16 pmol/mg protein in astroglial membranes and B(max) = 0.25 +/- 0.03 enhanced to 1.05 +/- 0.12 pmol/mg protein in cerebral endothelial membranes) but statistically unchanged affinity of the ligand for HA carrier (K(D) values calculated as 35.2 +/- 3.4 nM and 45.1 +/- 3.8 nM for astroglial bindings; whereas 25 +/- 2.1 nM and 30 +/- 2.6 nM for cerebral endothelial bindings of the amine). The compound VUF 8407 reduced the B(max) of zinc-exposed HA binding of astroglial membranes but did not modify the K(D) of the zinc-exposed membrane significantly. The ex vivo experiments confirmed our in vitro findings; an i.c.v. dose of 0.4 micromol/kg ZnSO(4,) 24 hr after the injection, enhanced the uptake of [(3)H]HA into dissociated hypothalamic and cerebellar cells to about 2- and 3-fold, respectively. Present data clearly showed that zinc exposures enhance the astroglial and the cerebral endothelial uptake of HA in vitro and it might be considered that zinc produces similar effects in vivo. Free zinc may participate in the regulation of the extraneuronal HA concentration and this metal ion (endogenous or exogenous) might be favored in the removal of the amine from the interstitial space especially in conditions with relatively high HA.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.